JFJoanne M. Fuller

Joanne M. Fuller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joanne M. Fuller has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Translating the Living with Medicines Questionnaire from English to Swedish: a validation study

    by Amélie Cransac, Barbra Katusiime, Hanna Gyllensten, Lilas Ali, Nicky Britten, Inger Ekman, Andreas Fors, Lina Hellström, Janet Krska, Karl Swedberg, et al.

    Aim: This study aimed to translate the Living with Medicines Questionnaire, version 3 (LMQ-3) into Swedish for validation in an outpatient cohort regularly using medicines. Methods: Phase 1 translated the originator questionnaire into Swedish, and tested face and content validity through cognitive interviews. Phase 2 tested validation through a cross-sectional survey. Exploratory factor analysis (EFA) of the 41 items in the LMQ-3 was conducted. Results: Phase 1 involved 25 cognitive interviews. In phase 2, 779 respondents completed the questionnaire online. The total mean LMQ-3 score was 90.6 (95% confidence interval (CI) 89.0–92.2; range 43–176), and the mean visual analogue scale score was 3.1 (95% CI 2.9–3.3; range 0–10). The median age was 72 years (range 21–96) with 80.9% retired. The mean number of prescribed medicines was 8.5 (SD 3.8) per respondent. EFA analyses revealed most items loaded in their original domains, except three items: ‘My medicines allow me to live my life as I want to’ (question (Q)32), ‘I have to put a lot of planning and thought into taking medicines’ (Q37) and ‘I find getting prescriptions from the doctor difficult’ (Q1). Conclusions: The LMQ-3 was successfully translated into Swedish and validated in a Swedish outpatient cohort regularly using medicines. Construct validity of the Swedish translation was adequate, with minor differences from the originator instrument. Future test–retest reliability will help assess suitability of the instrument for stability of scores over time and usefulness in longitudinal studies. In conclusion, this questionnaire can provide a person-centred measure of medicines burden in persons who regularly take prescribed medicines.

  • Open Access

    Integrating health promotion with and for older people - eHealth (IHOPe) – evaluating remote integrated person-centred care

    by Zahra Ebrahimi, Emmelie Barenfeld, Hanna Gyllensten, Patricia Olaya-Contreras, Andreas Fors, Eva Fredholm, Joanne M. Fuller, Mahboubeh Godarzi, Birgitta Krantz, Karl Swedberg, et al.

    Background: Healthcare and welfare systems worldwide are unprepared to accommodate the growing population of older people. Simultaneously, the cost of reactive care for older people is increasing. However, healthcare systems in many countries are reforming towards integrated and person-centred care with a focus on health promotion and proactive actions.The Integrating Health Promotion with and for Older People – eHealth (IHOPe)project aims to describe and evaluate a person-centred e-support intervention that promotes a sustainable partnership between community-dwelling frail older people and health and social care professionals.Methods: The IHOPe project is designed as a randomised controlled trial comparing a control group receiving standard care with an intervention group receiving standard care and add-on person-centred care through telephone support and a digital platform. The primary outcome measure is a composite score of changes in general self-efficacy and the need for unscheduled hospital care. The project is conducted in Gothenburg, Sweden. At least 220 participants aged ≥ 75 years will be included after being screened using a frailty instrument. The study design, intervention components, digital platform, and questionnaires were developed in close collaboration with an advisory group of inter-professional researchers, stakeholders, clinicians, and older representatives. Data will mainly be collected through questionnaires at baseline and 3, 6, and 12 months after inclusion in the study. Recruitment is ongoing and should be completed during 2023. Data will be analysed using quantitative and qualitative methods. The evaluation will include effectiveness, process, and health economics. The study was approved by the Regional Ethical Review Board in Gothenburg, Sweden (Dnr 2019–05364, Dnr 2020–03550, Dnr 2021–03255).Discussion: The findings will expand our knowledge of remotely integrated person-centred care for frail older people. Thereby, the IHOPe project is expected to fill highlighted knowledge gaps on intervention evaluations including the triad of person-centred, digital, and integrated care elements, as well as economic evaluations of remote health services for frail older people. The study is ongoing, and the results are not completed but if they turn out to be positive, implementation is not limited to time or location.Trial registration: ClinicalTrial.gov: NCT04416815. Registered 07/06/2021.


  • Open Access

    Commentary: how person-centred is pharmaceutical care?

    by Hanna Gyllensten, Joanne M. Fuller, Malin Johansson Östbring

    Health systems in many countries are currently undergoing an evolution towards more person-centred care. However, an overview of the literature shows that there is little or no guidance available on how to apply person-centred care to pharmaceutical care and clinical pharmacy practices. In this paper we apply a model for person-centred care created by a national multidisciplinary research centre in Gothenburg, Sweden, to the clinical work tasks of outpatient and inpatient pharmacists and describe how pharmaceutical care can become more person-centred.


  • Open Access

    Why do patients struggle with their medicines?—A phenomenological hermeneutical study of how patients experience medicines in their everyday lives

    by Joanne M. Fuller, Emmelie Barenfeld, Inger Ekman

    Why do so many people struggle with their medicines despite decades of research on medicines taking? Research into how people experience medicines in their everyday life remains scarce with the majority of research in this area of focusing on whether or not people take their medicines as prescribed. Hence, this study used a phenomenological hermeneutical qualitative design to gain a deeper understanding of individuals’ perspectives on the lived experience of medicine-taking. Findings from this study highlight five main themes where participants experience medicines as: 1) life-saving and indispensable, 2) normal and a daily routine, 3) confusing and concerning, 4) unsuitable without adjustment, and 5) intrusive and unwelcome. These results can be the basis for mutually agreed prescribing through a co-creative approach that aims at enhancing open and honest dialogues between patients and healthcare professionals in partnership about medicines.


  • Testing evidence routine practice: Using an implementation framework to embed a clinically proven asthma service in Australian community pharmacy

    by Joanne M. Fuller, Bandana Saini, Sinthia Bosnic-Anticevich, Victoria Garcia Cardenas, Shalom I. Benrimoj, Carol Armour


  • Dispensing good sleep health behaviours not pills – a cluster‐randomized controlled trial to test the feasibility and efficacy of pharmacist‐provided brief behavioural treatment for insomnia

    by Joanne M. Fuller, Keith K. Wong, Camilla Hoyos, Ines Krass, Bandana Saini

    Summary: Behavioural therapies are recommended as the first‐line treatment of insomnia; however, sedatives and hypnotics constitute the main treatment modality used in primary care. Community pharmacies provide a unique conduit for identifying and providing appropriate treatment for those with insomnia either purchasing prescription sedatives or seeking over‐the‐counter treatments. A feasibility study using a cluster‐randomized controlled trial, testing the efficacy of trained pharmacists providing behavioural interventions such as stimulus control and sleep restriction to patients with insomnia, in improving insomnia severity was conducted. The intervention involved three pharmacy visits (baseline, 1 and 3 months follow‐up). The control group received usual care and information sheets on insomnia. The primary outcome was the Insomnia Severity Index. Twelve community pharmacists (five control, seven intervention) in New South Wales, Australia were recruited and trained. These pharmacists, in turn, recruited 46 patients (22 control, 24 intervention (mean age 53.7 ± 18.4, 72% females) and delivered a brief behavioural therapy intervention. The overall decrease in Insomnia Severity Index from baseline to the 3‐month follow‐up in the intervention group, n = 17 (7.6 ± 4.3 points), was significantly greater than for the control group, n = 19 (2.9 ± 8.8 points) (mean difference 4.6, 95% confidence interval: 0.005–9.2, P = 0.05). However, when the effect of clustering was taken into account using a mixed‐effects model, the estimated difference in Insomnia Severity Index (change from baseline to visit 3) between the intervention and control groups was not significant (group difference in Insomnia Severity Index change = 3.78, 95% confidence interval: −0.81 to 8.37, P = 0.11; intracluster correlation = 0.18). The study highlights the use of a novel venue to deliver brief behavioural therapies for insomnia using trained non‐psychologist health professionals. Although, when cluster effect was taken into account, the difference in Insomnia Severity Index reduction between the intervention versus control groups was non‐significant, the results highlight that reductions in insomnia severity can be gained using trained pharmacists providing brief behavioural interventions. Future research in this area is warranted, with appropriately sized studies using the conventional, robust randomized trial design.


  • Open Access

    A Comparison of Screening Methods for Sleep Disorders in Australian Community Pharmacies: A Randomized Controlled Trial

    by Joanne M. Fuller, Keith K. Wong, Ronald Grunstein, Ines Krass, Jayshree Patel, Bandana Saini

    Community pharmacies may potentially assist in screening for chronic conditions such as sleep disorders, which remain both under-diagnosed and untreated. We aimed to compare a subjective risk-assessment-only questionnaire (RAO) for common sleep disorder screening against the same risk-assessment questionnaire plus a nasal flow monitor as an objective marker of possible underlying obstructive sleep apnea (OSA) (RA+) in a community pharmacy setting. The primary outcome was the number of participants identified in RAO or RA+ group who were likely to have and consequently be diagnosed with OSA. Further outcomes included the number of participants identified as being at risk for, referred for, taking-up referral for, and then diagnosed with OSA, insomnia, and/or restless legs syndrome (RLS) in either group. In a cluster-randomized trial, participants were recruited through 23 community pharmacies. Using validated instruments, 325 (RAO = 152, RA+ = 173) participants were screened for OSA, insomnia, and RLS. 218 (67%) participants were at risk of OSA, insomnia or RLS and these participants were referred to their primary physician. The proportion of screened participants identified as being at risk of OSA was significantly higher in the RA+ group (36% in RAO vs. 66% in RA+, OR 3.4, 95% CI (1.8–6.5), p<0.001). A 12-month follow-up was completed in 125 RAO and 155 RA+ participants. Actual referral uptake was 34% RAO, 26% RA+, OR 4.4, 95% CI (1.4–19.2), p = 0.31. The OSA diagnosis rate was higher in the RA+ arm (p = 0.01). To yield a single additional confirmed OSA diagnosis, 16 people would need to be screened using the RA+ protocol. These results demonstrate that utilising either screening method is feasible in identifying individuals in the community pharmacy setting who are likely to have OSA, insomnia and/or RLS. Secondly, adding an objective marker of OSA to a questionnaire-based prediction tool resulted in more confirmed OSA diagnoses. : ACTR.org.au ACTRN12608000628347


  • Open Access

    Standardizing care in medical oncology

    by Isla M. Hains, Joanne M. Fuller, Robyn L. Ward, Sallie‐Anne Pearson

    BACKGROUND: Medical oncology is embracing information technology to standardize care and improve patient outcomes, with a range of Web‐based systems used internationally. The authors' aim was to determine the factors affecting the uptake and use of a Web‐based protocol system for medical oncology in the Australian setting.METHODS: The authors conducted 50 interviews and observed medical oncology physicians, nurses, and pharmacists in their treatment setting at 6 hospitals in different geographic locations.RESULTS: The Web‐based system plays a major role in guiding oncology treatment across participating sites. However, its use varies according to hospital location, clinician roles, and experience. A range of issues impact on clinicians' attitudes toward and use of the Web‐based system. Important factors are clinician‒specific (eg, their need for autonomy and perceptions of lack of time) or environmental (eg, hospital policy on protocol use, endorsement of the system, and the availability of appropriate infrastructure, such as sufficient computers). The level of education received regarding the system was also found to be integral to its ongoing use.CONCLUSIONS: Although the provision of high‐quality evidence‐based resources, electronic or otherwise, is essential for standardizing care and improving patient outcomes, the authors' findings demonstrate that this alone does not ensure uptake. It is important to understand end‐users, the environment in which they operate, and the basic infrastructure required to implement such a system. Implementation must also be accompanied by continuing education and endorsement to ensure both long‐term sustainability and use of the system to its full potential. Cancer 2009. © 2009 American Cancer Society.


  • The development of a sleep disorder screening program in Australian community pharmacies

    by Adam Tran, Joanne M. Fuller, Keith K. Wong, Ines Krass, Ron Grunstein, Bandana Saini

    Objective To develop, pilot and determine the feasibility of a sleep-specific screening and awareness program in community pharmacies. Setting The screening was piloted in five Australian community pharmacies. Method The Pharmacy Tool for Assessment of Sleep Health was constructed by drawing on known relationships between sleep disorders, and lifestyle factors, medical conditions and medications. Four validated instruments were used in the screening tool: the Epworth Sleepiness Scale (ESS), Insomnia Severity Index (ISI), Multivariable Apnea Prediction Index (MAPI) and International Restless Legs Syndrome Study Group Screening Criteria (IRLS). These instruments were used to predict the participant’s risk of a sleep disorder and the results were compared with reported lifestyle, medical and medication factors. On-site training of consenting pharmacists was provided, followed by an eight week client recruiting and screening period. Feedback was elicited from participating pharmacists and clients. Main outcome measure The feasibility of, and trends found from, the developed screening tool and protocol. Results Of 167 clients who requested or were invited to participate by pharmacists, 84 (50.3%) were screened. Analysis of collected data indicated that 33.3%, 21.4% and 27.4% of participants were at risk of having or developing insomnia, obstructive sleep apnea (OSA) and restless legs syndrome (RLS) respectively, while 38.1% were not at risk of any of the screened disorders. OSA odds increased 12.8 times (95% CI: 3.2–50.4) with diabetes and 4.9 times (1.2–20.9) with opioid use, while shift workers were 8.4 times (1.6–43.2) more likely to have insomnia. Participants and pharmacists reported the screening protocol and instrument was user friendly and feasible. Conclusion The development and pilot of this screening tool was successful. The prevalence of sleep disorders in the sampled population was high but generally consistent with previous studies on the general population. Furthermore, associations found may form a foundation for a clinical algorithm to identify those at a higher risk of having or developing a sleep disorder. Further work is required to validate this screening tool in the community pharmacy context.